4//SEC Filing
Erickson Bruce Kipp 4
Accession 0001493152-21-026393
CIK 0001833214other
Filed
Oct 25, 8:00 PM ET
Accepted
Oct 26, 9:53 PM ET
Size
6.6 KB
Accession
0001493152-21-026393
Insider Transaction Report
Form 4
Erickson Bruce Kipp
Chief Operating Officer
Transactions
- Award
Employee Stock Option (right to buy)
2021-10-22+232,642→ 232,642 totalExercise: $1.88Exp: 2031-05-27→ Common Stock (232,642 underlying)
Footnotes (2)
- [F1]Pursuant to the Agreement and Plan of Merger, dated June 21, 2021 and as amended August 12, 2021 (the "Business Combination Agreement"), by and among Big Cypress Acquisition Corp. ("BCYP"), Big Cypress Merger Sub Inc., and SAB Biotherapeutics, Inc. ("Old SAB Biotherapeutics"), each security to purchase shares of Old SAB Biotherapeutics common stock issued and outstanding immediately prior to the effective time of the transactions contemplated by the Business Combination Agreement was automatically converted into a security to purchase a number of shares of the Issuer's common stock based on a conversion rate of $10.10. Upon consummation of the business combination, BCYP changed its name to "SAB Biotherapeutics, Inc." ("New SAB Biotherapeutics" or "Issuer").
- [F2]The option shall vest and become exercisable over a period of 36 months from the Vesting Start Date, March 1, 2021, with 1/3 vesting on the first anniversary of the Vesting Start Date and the remaining balance to vest on a monthy basis for a period of 24 months thereafter, such that the option will be fully vested 36 months from the Vesting Start Date, subject to the reporting person's continuous service with the Issuer on each such date.
Documents
Issuer
SAB Biotherapeutics, Inc.
CIK 0001833214
Entity typeother
Related Parties
1- filerCIK 0001889685
Filing Metadata
- Form type
- 4
- Filed
- Oct 25, 8:00 PM ET
- Accepted
- Oct 26, 9:53 PM ET
- Size
- 6.6 KB